No Data
No Data
Express News | Rani Therapeutics Holdings: Phase 1 Clinical Study for Rt-114 for Treatment of Obesity Expected to Initiate in Mid- 2025
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist
Express News | Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of Rt-114, a GLP-1/Glp-2 Dual Agonist (Pg-102) Delivered Orally via the Ranipill® Capsule, to Subcutaneously Administered Pg-102
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
BTIG Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $14
Promising Potential of Rani Therapeutics: A Buy Rating on RT-114's Market Prospects
mrBoxes : yeah surprising - I can't see any news or announcements.
Amhbflzuanusmoney888 OP mrBoxes : Not dare to average down yet. Didn't know where to stop.